Arhalofenate: Preliminary Phase II data

Preliminary data from an open-label, U.S. Phase II trial in 32 patients with gout showed that 7%, 43% (p<0.05) and 79% of patients receiving once-daily 600 mg oral arhalofenate plus 40 mg febuxostat and 20%, 93% (p<0.001) and 100% (p<0.01) of patients receiving once-daily 800 mg oral arhalofenate plus 40 mg febuxostat achieved sUA levels of <4, <5 and <6 mg/dL at day 29, respectively, vs. 0%, 7% and 47% of patients receiving 40 mg febuxostat. Additionally, 31%, 88% and 94% of patients receiving once-daily 600 mg oral arhalofenate plus 80 mg febuxostat and 79% (p<0.05), 93% and 100% of patients receiving once-daily 800 mg oral arhalofenate plus 80 mg febuxostat achieved sUA levels of <4, <5 and <6 mg/dL at day 29, respectively, vs. 29%, 71% and 93% of patients receiving 80 mg febuxostat. ...